Positive results about MDV3100

[Guest guest]

Positive Data From Phase I/II Trial Of MDV3100 for men

with Advanced Prostate Cancer It was announced today that the phase I/II trial of MDV3100 demonstrated

positive results. MDV3100 is a novel triple-acting oral androgen receptor antagonist, the common antagonist most of us are familiar with today is Casodex.  These positive results included men with advanced disease who have already failed both hormone therapy and chemotherapy.There is a phase III trial (AFFIRM) currently recruiting men.Go to www.advancedprostatecancer.net to learn about advanced prostate cancer or to http://advancedprostatecancer.net/?p=1458 to read this post about MDV3100. 

-- T Nowak MA, MSWDirector for Advocacy and  Advanced Prostate Cancer Programs, Malecare Inc. Men Fighting Cancer, TogetherSurvivor - Thyroid, Recurrent Prostate and Renal Cancers

www.advancedprostatecancer.net - A blog about advanced and recurrent prostate cancerwww.malecare.com - information and support about prostate cancer

http://health.groups.yahoo.com/group/advancedprostatecancer/ - an online support group for men and their families diagnosed with advanced and recurrent prostate cancer